Factor D.


Journal

Immunological reviews
ISSN: 1600-065X
Titre abrégé: Immunol Rev
Pays: England
ID NLM: 7702118

Informations de publication

Date de publication:
01 2023
Historique:
pubmed: 2 11 2022
medline: 20 1 2023
entrez: 1 11 2022
Statut: ppublish

Résumé

Complement factor D (FD) is a serine protease that plays an essential role in the activation of the alternative pathway (AP) by cleaving complement factor B (FB) and generating the C3 convertases C3(H

Identifiants

pubmed: 36316810
doi: 10.1111/imr.13155
doi:

Substances chimiques

Complement Factor D EC 3.4.21.46
Mannose-Binding Protein-Associated Serine Proteases EC 3.4.21.-
Complement System Proteins 9007-36-7
MASP-3 protein, mouse EC 3.4.21.-

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-24

Informations de copyright

© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Morgan BP. Complement: Clinical Aspects and Relevance to Disease. Academic Press; 1990:228.
Killick J, Morisse G, Sieger D, Astier AL. Complement as a regulator of adaptive immunity. Semin Immunopathol. 2018;40:37-48.
Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785-797.
Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058-1066.
Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat Rev Immunol. 2002;2:346-353.
Lachmann PJ, Halbwachs L. The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol. 1975;21:109-114.
Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med. 1981;154:856-867.
Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med. 2008;12:1074-1084.
Whaley K. Biosynthesis of the complement components and the regulatory proteins of the alternative complement pathway by human peripheral blood monocytes. J Exp Med. 1980;151:501-516.
Cook KS, Min HY, Johnson D, et al. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science. 1987;237:402-405.
Choy LN, Rosen BS, Spiegelman BM. Adipsin and an endogenous pathway of complement from adipose cells. J Biol Chem. 1992;267:12736-12741.
White RT, Damm D, Hancock N, et al. Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem. 1992;267:9210-9213.
Gómez-Banoy N, Guseh JS, Li G, et al. Adipsin preserves beta cells in diabetic mice and associates with protection from type 2 diabetes in humans. Nat Med. 2019;25:1739-1747.
Barnum SR, Schein TN. The Complement FactsBook. 2nd ed. Academic Press; 2018:514.
Volanakis JE, Barnum SR, Kilpatrick JM. Purification and properties of human factor D. Methods Enzymol. 1993;223:82-97.
Takahashi M, Ishida Y, Iwaki D, et al. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J Exp Med. 2010;207:29-37.
Fearon DT, Austen KF, Ruddy S. Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med. 1974;139:355-366.
Taylor FR, Bixler SA, Budman JI, et al. Induced fit activation mechanism of the exceptionally specific serine protease, complement factor D. Biochemistry. 1999;38:2849-2859.
Barnum SR, Niemann MA, Kearney JF, Volanakis JE. Quantitation of complement factor D in human serum by a solid-phase radioimmunoassay. J Immunol Methods. 1984;67:303-309.
Volanakis JE, Barnum SR, Giddens M, Galla JH. Renal filtration and catabolism of complement protein D. N Engl J Med. 1985;312:395-399.
Xu Y, Ma M, Ippolito GC, Schroeder HW Jr, Carroll MC, Volanakis JE. Complement activation in factor D-deficient mice. Proc Natl Acad Sci U S A. 2001;98:14577-14582.
Skjoedt MO, Hummelshoj T, Palarasah Y, et al. A novel mannose-binding lectin/ficolin-associated protein is highly expressed in heart and skeletal muscle tissues and inhibits complement activation. J Biol Chem. 2010;285:8234-8243.
Degn SE, Jensen L, Hansen AG, et al. Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway activation. J Immunol. 2012;189:3957-3969.
Thielens NM, Cseh S, Thiel S, et al. Interaction properties of human mannan-binding lectin (MBL)-associated serine proteases-1 and -2, MBL-associated protein 19, and MBL. J Immunol. 2001;166:5068-5077.
Phillips AE, Toth J, Dodds AW, et al. Analogous interactions in initiating complexes of the classical and lectin pathways of complement. J Immunol. 2009;182:7708-7717.
Teillet F, Gaboriaud C, Lacroix M, Martin L, Arlaud GJ, Thielens NM. Crystal structure of the CUB1-EGF-CUB2 domain of human MASP-1/3 and identification of its interaction sites with mannan-binding lectin and ficolins. J Biol Chem. 2008;283:25715-25724.
Kusakari K, Machida T, Ishida Y, et al. The complex formation of MASP-3 with pattern recognition molecules of the lectin complement pathway retains MASP-3 in the circulation. Front Immunol. 2022;13:907023.
Ambrus G, Gál P, Kojima M, et al. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: a study on recombinant catalytic fragments. J Immunol. 2003;170:1374-1382.
Degn SE, Jensenius JC, Thiel S. Disease-causing mutations in genes of the complement system. Am J Hum Genet. 2011;88:689-705.
Degn S, Jensen L, Olszowski T, Jensenius JC, Thiel S. Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44. J Immunol. 2013;191:1334-1345.
Matsushita M, Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel C1s-like serine protease. J Exp Med. 1992;176:1497-1502.
Thiel S, Vorup-Jensen T, Stover CM, et al. A second serine protease associated with mannan-binding lectin that activates complement. Nature. 1997;386:506-510.
Dahl MR, Thiel S, Matsushita M, et al. MASP-3 and its association with distinct complexes of the mannan-binding lectin complement activation pathway. Immunity. 2001;15:127-135.
Iwaki D, Kanno K, Takahashi M, et al. Small mannose-binding lectin-associated protein plays a regulatory role in the lectin complement pathway. J Immunol. 2006;177:8626-8632.
Iwaki D, Kanno K, Takahashi M, Endo Y, Matsushita M, Fujita T. The role of mannose-binding lectin-associated serine protease-3 in activation of the alternative complement pathway. J Immunol. 2011;187:3751-3758.
Dobó J, Szakács D, Oroszlán G, et al. MASP-3 is the exclusive pro-factor D activator in resting blood: the lectin and the alternative complement pathways are fundamentally linked. Sci Rep. 2016;6:31877.
Pihl R, Jensen L, Hansen AG, et al. Analysis of factor D isoforms in Malpuech-Michels-Mingarelli-Carnevale patients highlights the role of MASP-3 as a maturase in the alternative pathway of complement. J Immunol. 2017;199:2158-2170.
Oroszlán G, Dani R, Szilágyi A, et al. Extensive basal level activation of complement mannose-binding lectin-associated serine protease-3: kinetic modeling of lectin pathway activation provides possible mechanism. Front Immunol. 2017;8:1821.
Hayashi M, Machida T, Ishida Y, et al. Cutting Edge: Role of MASP-3 in the physiological activation of factor D of the alternative complement pathway. J Immunol. 2019;203:1411-1416.
Oroszlán G, Dani R, Végh BM, et al. Proprotein convertase is the highest-level activator of the alternative complement pathway in the blood. J Immunol. 2021;206:2198-2205.
Dobó J, Kocsis A, Dani R, Gál P. Proprotein convertases and the complement system. Front Immunol. 2022;13:958121.
Sirmaci A, Walsh T, Akay H, et al. MASP1 mutations in patients with facial, umbilical, coccygeal, and auditory findings of Carnevale, Malpuech, OSA, and Michels syndromes. Am J Hum Genet. 2010;87:679-686.
Rooryck C, Diaz-Font A, Osborn DPS, et al. Mutations in lectin complement pathway genes COLEC11 and MASP1 cause 3MC syndrome. Nat Genet. 2011;43:197-203.
Munye MM, Diaz-Font A, Ocaka L, et al. COLEC10 is mutated in 3MC patients and regulates early craniofacial development. PLoS Genet. 2017;13:e1006679.
Sprong T, Roos D, Weemaes C, et al. Deficient alternative complement pathway activation due to factor D deficiency by 2 novel mutations in the complement factor D gene in a family with meningococcal infections. Blood. 2006;107:4865-4870.
Lo JC, Ljubicic S, Leibiger B, et al. Adipsin is an adipokine that improves β cell function in diabetes. Cell. 2014;158:41-53.
Sim RB, Reboul A, Arlaud GH, Villiers CL, Colomb MG. Interaction of 125I-labelled complement subcomponents C1r and C1s with protease inhibitors in plasma. FEBS Lett. 1979;97:111-115.
Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol. 2000;165:2637-2642.
Gigli I, Fujita T, Nussenzweig V. Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A. 1979;76:6596-6600.
Fearon DT. Cellular receptors for fragments of the third component of complement. Immunol Today. 1984;5:105-110.
Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution. J Exp Med. 1977;146:257-270.
Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein decay-accelerating factor. Proc Natl Acad Sci U S A. 1983;80:5066-5070.
Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A. 1983;80:5430-5434.
Lesavre PH, Müller-Eberhard HJ. Mechanism of action of factor D of the alternative complement pathway. J Exp Med. 1978;148:1498-1509.
Volanakis VE, Narayana SVL. Complement factor D, a novel serine protease. Protein Sci. 1996;5:553-564.
Sanders PW, Volanakis JE, Rostand SG, Galla JH. Human complement protein D catabolism by the rat kidney. J Clin Invest. 1986;77:1299-1304.
Pascual M, Steiger G, Estreicher J, Macon K, Volanakis JE, Schifferli JA. Metabolism of complement factor D in renal failure. Kidney Int. 1988;34:529-536.
Kluin-Nelemans HC, van Velzen-Blad H, van Helden HP, Daha MR. Functional deficiency of complement factor D in a monozygous twin. Clin Exp Immunol. 1984;58:724-730.
Hiemstra PS, Langeler E, Compier B, et al. Complete and partial deficiencies of complement factor D in a Dutch family. J Clin Invest. 1989;84:1957-1961.
Weiss SJ, Ahmed AE, Bonagura VR. Complement factor D deficiency in an infant first seen with pneumococcal neonatal sepsis. J Allergy Clin Immunol. 1998;102:1043-1044.
Biesma DH, Hannema AJ, van Velzen-Blad H, et al. A family with complement factor D deficiency. J Clin Invest. 2001;108:233-240.
Arlaud GJ, Volanakis JE, Thielens NM, et al. The atypical serine proteases of the complement system. Adv Immunol. 1998;69:249-307.
Sng CCT, O'Byrne S, Prigozhin DM, et al. A type III complement factor D deficiency: structural insights for inhibition of the alternative pathway. J Allergy Clin Immunol. 2018;142:311-314.
Agaoglu NB, Akgun DO. Further expansion of the mutational spectrum of 3MC syndrome: a novel MASP1 pathogenic variant in a male patient. Mol Syndromol. 2021;12:379-385.
Atik T, Koparir A, Bademci G, et al. Novel MASP1 mutations are associated with an expanded phenotype in 3MC1 syndrome. Orphanet J Rare Dis. 2015;10:128.
Ruseva MM, Takahashi M, Fujita T, Pickering MC. C3 dysregulation due to factor H deficiency is mannan-binding lectin-associated serine proteases (MASP)-1 and MASP-3 independent in vivo. Clin Exp Immunol. 2014;176:84-92.
Hoffmann JA, Kafatos FC, Janeway CA Jr, Ezekowitz RAB. Phylogenetic perspectives in innate immunity. Science. 1999;284:1313-1318.
Müller WEG, Blumbach B, Müller IM. Evolution of the innate and adaptive immune systems: relationships between potential immune molecules in the lowest metazoan phylum (Porifera) and those in vertebrates. Transplantation. 1999;68:1215-1227.
Zarkadis IK, Mastellos D, Lambris JD. Phylogenetic aspects of the complement system. Dev Comp Immunol. 2001;25:745-762.
Riesgo A, Farrar N, Windsor PJ, Giribet G, Leys SP. The analysis of eight transcriptomes from all poriferan classes reveals surprising genetic complexity in sponges. Mol Biol Evol. 2014;31:1102-1120.
Poole AZ, Kitchen SA, Weis VM. The role of complement in cnidarian-dinoflagellate symbiosis and immune challenge in the sea anemone Aiptasia pallida. Front Microbiol. 2016;7:519.
Fujita T, Endo Y, Nonaka M. Primitive complement system--recognition and activation. Mol Immunol. 2004;41:103-111.
Nonaka M. Evolution of the complement system. Subcell Biochem. 2014;80:31-43.
Matsushita M. The complement system of agnathans. Front Immunol. 2018;9:1405.
Endo Y, Nonaka M, Saiga H, et al. Origin of mannose-binding lectin-associated serine protease (MASP)-1 and MASP-3 involved in the lectin complement pathway traced back to the invertebrate, amphioxus. J Immunol. 2003;170:4701-4707.
Ding C, Xiao T, Qin B, Xu B, Lv Z, Wang H. Functional identification of complement factor D and analysis of its expression during GCRV infection in grass carp (Ctenopharyngodon idella). Int J Mol Sci. 2021;22:12011.

Auteurs

Hideharu Sekine (H)

Department of Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Takeshi Machida (T)

Department of Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan.

Teizo Fujita (T)

Fukushima Prefectural General Hygiene Institute, Fukushima, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH